FSZ - ETF AI Analysis

Top Page

First Trust Switzerland AlphaDEX Fund (FSZ)

Rating:63Neutral

Price Target:―

FSZ, the First Trust Switzerland AlphaDEX Fund, has a solid overall rating that reflects a mix of strong Swiss companies and a few holdings with financial or valuation challenges. Higher-quality positions like Holcim, Roche, Galenica, Galderma, and SFS Group support the fund with strong financial performance, attractive or fair valuations, and generally positive or stable technical trends. However, weaker names such as Barry Callebaut, with high leverage and negative cash flows, and holdings facing bearish technical trends or overvaluation concerns introduce risk, and the fund is also exposed to the broader risk of concentration in the Swiss market.

Positive Factors

Improving Recent Performance

The ETF has shown solid gains over the last three months and slightly positive results so far this year, indicating improving momentum.

Supportive Top Holdings

Several of the largest positions, such as Sandoz, Roche, and EFG International, have delivered strong year-to-date performance, helping support the fund’s returns.

Diversified Swiss Sector Exposure

Holdings spread across health care, industrials, financials, and consumer-related sectors help reduce the impact of weakness in any single industry within Switzerland.

Negative Factors

High Country Concentration

With the vast majority of assets invested in Swiss companies, the fund is heavily exposed to economic and market conditions in Switzerland.

Weakness in Several Top Holdings

A number of major positions, including Holcim, Barry Callebaut, Galenica, Adecco, Bucher Industries, and Galderma, have shown weak year-to-date performance, which can drag on overall returns.

Relatively High Expense Ratio

The fund’s expense ratio is on the higher side for an ETF, which means more of the investment return is used to cover fees.

FSZ vs. SPDR S&P 500 ETF (SPY)

AUM45.66M

RegionEurope

Expense Ratio0.80%

Beta0.62

IssuerFirst Trust

Inception DateFeb 14, 2012

Dividend Yield1.74%

Asset ClassEquity

Index TrackedNASDAQ AlphaDEX Switzerland Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume1,476

30 Day Avg. Volume1,058

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

87.74

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering40

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

FSZ Summary

FSZ is an exchange-traded fund that follows the NASDAQ AlphaDEX Switzerland Index, giving you broad exposure to Swiss stocks. It focuses on many types of companies, including health care, industrials, and financials. Well-known names in the fund include Roche Holding and Holcim. Someone might invest in FSZ to diversify outside the U.S. and tap into Switzerland’s mix of stable, defensive businesses and growth opportunities. A key risk is that the fund is concentrated in one country, so its value can rise or fall with the Swiss stock market and economy.

How much will it cost me?The expense ratio for the First Trust Switzerland AlphaDEX Fund (FSZ) is 0.8%, which means you’ll pay $8 per year for every $1,000 invested. This is higher than the average for ETFs because it is actively managed, using a rules-based strategy to select stocks with growth and value potential. Actively managed funds typically have higher costs due to the additional research and management involved.

What would affect this ETF?The FSZ ETF, which focuses on Swiss equities, could benefit from Switzerland's strong reputation for economic stability and innovation, particularly in sectors like healthcare and finance. Positive trends such as advancements in pharmaceuticals or growth in financial services could drive the ETF's performance. However, potential risks include economic slowdowns in Europe, regulatory changes affecting key sectors, or global market volatility, which could negatively impact the ETF's holdings and overall returns.

FSZ Top 10 Holdings

FSZ is leaning into Switzerland’s industrial and health-care backbone, with names like Sandoz and Roche doing much of the heavy lifting as their shares keep rising on solid momentum and strong fundamentals. Financial player EFG International is also pulling its weight, adding a value-and-income tilt. On the flip side, staffing giant Adecco and machinery maker Bucher Industries have been lagging, acting as a bit of a brake on returns, while consumer-focused Barry Callebaut looks mixed. Overall, it’s a Switzerland-centric, sector-diversified bet with no single stock dominating the story.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
SDZ	Sandoz Group Ltd	4.35%	$1.91M	CHF26.95B	66.43%	59 Neutral
SFSN	SFS Group AG	4.31%	$1.89M	CHF4.43B	1.78%	72 Outperform
HOLN	Holcim	4.28%	$1.87M	CHF43.64B	-9.50%	73 Outperform
BARN	Barry Callebaut AG	4.22%	$1.85M	CHF7.36B	40.54%	54 Neutral
ADEN	Adecco Group AG	4.11%	$1.80M	CHF3.89B	-0.73%	65 Neutral
GALE	Galenica AG	4.10%	$1.79M	CHF4.86B	18.80%	70 Outperform
BUCN	Bucher Industries AG	3.99%	$1.75M	CHF3.66B	0.97%	65 Neutral
GALD	Galderma Group AG	3.74%	$1.64M	CHF34.52B	25.28%	70 Outperform
SCMN	Swisscom AG	3.62%	$1.59M	CHF32.89B	25.79%	67 Neutral
ROG	Roche Holding AG	3.55%	$1.55M	CHF283.12B	42.92%	73 Outperform

FSZ Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

80.01

Positive

100DMA

78.44

Positive

200DMA

77.00

Positive

Market Momentum

MACD

0.91

Positive

RSI

62.12

Neutral

STOCH

50.77

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FSZ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 82.09, equal to the 50-day MA of 80.01, and equal to the 200-day MA of 77.00, indicating a bullish trend. The MACD of 0.91 indicates Positive momentum. The RSI at 62.12 is Neutral, neither overbought nor oversold. The STOCH value of 50.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSZ.

FSZ Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
FSZ	―	―	$45.66M	0.80%	―
EWL	―	―	$1.66B	0.50%	―
FKU	―	―	$94.18M	0.80%	―
FGM	―	―	$90.37M	0.80%	―
EUDG	―	―	$74.47M	0.58%	―
FLSW	―	―	$68.33M	0.09%	―

Performance Comparison

FSZ

First Trust Switzerland AlphaDEX Fund

83.57

18.00

27.45%

EWL

iShares MSCI Switzerland ETF

―

FKU

First Trust United Kingdom AlphaDEX Fund

―

FGM

First Trust Germany AlphaDEX Fund

―

EUDG

WisdomTree Europe Quality Dividend Growth Fund

―

FLSW

Franklin FTSE Switzerland ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents